论文部分内容阅读
观察重组组织型纤溶酶原激活剂(recombinant tissue-type plasminogen activator, rt-PA)治疗急性心肌梗死的疗效。方法: 53例急性心肌梗死患者,于 60min或 90min内给予rt-PA总量为 50 mg,观察血管再通的临床指标、低血压、出血及寒战等并发症。结果:总血管再通42例(42/53),其中,60 min组及90 min组再通者分别有19例(19/28)、23例(23/25)。不良反应发生中,一过性低血压6例(6/53),轻度出血7例(7/53),发生寒战 1例(1/53),一般不需处理自行消失。结论:rt-PA是一种安全、有效的溶栓剂。
To observe the curative effect of recombinant tissue-type plasminogen activator (rt-PA) on acute myocardial infarction. Methods: Fifty-three patients with acute myocardial infarction were given rt-PA for 60 minutes or 90 minutes. The total amount of rt-PA was 50 mg. The clinical indexes of recanalization, such as hypotension, hemorrhage and chills were observed. Results: Twenty-four patients (42/53) had total revascularization. Among them, 19 (19/28) and 23 (23/25) were recanalized for 60 min and 90 min respectively. Adverse reactions occurred in 6 cases of transient hypotension (6/53), mild bleeding in 7 cases (7/53), cholera occurred in 1 case (1/53), generally do not need to deal with their own disappear. Conclusion: rt-PA is a safe and effective thrombolytic agent.